CLAIMS

1. Composition having an activity on the proliferation of clonogenic cells in tumours and which comprises a therapeutically effective quantity of an isoflavonoid or of an analogue of the chromone type.

2. Composition according to Claim 1, in which the isoflavonoid is chosen from the compounds of formula:



(I)

in which formula:

- R_1, R_2, R_3 and R_4 are chosen, independently of each other, from H, OH, a C_1-C_4 alkoxy group, an $-OCOR_7$ group, R_7 being a C_1-C_4 alkyl group, at least one of the substituents R_1, R_2, R_3 or R_4 being other than H and it being possible for R_2 and R_3 to form together a methylenedioxy group,
- R_5 is chosen from H, OH, a C_1-C_4 alkoxy group, an O-glycosyl group and a cyclohexyl group,
- R_6 is chosen from a cyclohexyl group, a phenyl group and a phenyl group substituted 1 to 3 times with groups chosen from H, OH and a C_1-C_4 alkoxy group,
- and —— denotes either a double bond, or a single bond.

3. Composition according to Claim 2, in which the isoflavonoid is chosen from genistein, daidzein and biochanin A.

4. Use of an isoflavonoid or of an analogue of the chromone type for the manufacture of a medicament intended to interfere with the generation of clonogenic

cells in tumours during a treatment of these tumours with at least one cytotoxic agent.

5. Use of a compound chosen from the compounds of formula:



(I)

in which formula:

- R_1, R_2, R_3 and R_4 are chosen, independently of each other, from H, OH, a C_1-C_4 alkoxy group, an $-OCOR_7$ group, R_7 being a C_1-C_4 alkyl group, at least one of the substituents R_1, R_2, R_3 or R_4 being other than H and it being possible for R_2 and R_3 to form together a methylenedioxy group,
- R_5 is chosen from H, OH and a C_1-C_4 alkoxy group, an O-glycosyl group, and a cyclohexyl group,
- R_6 is chosen from a cyclohexyl group, a phenyl group and a phenyl group substituted 1 to 3 times with groups chosen from H, OH and a C_1-C_4 alkoxy group,
- and —— ..... denotes either a double bond, or a single bond,

for the manufacture of a medicament intended to interfere with the generation of clonogenic cells in tumours during a treatment of these tumours with at least one cytotoxic agent.

6. Use according to Claim 5, in which the compound of formula I is chosen from genistein, daidzein and biochanin A.

7. Method for the chemotherapeutic treatment of a tumour in a patient with at least one cytotoxic agent, which comprises the administration, during the treatment with the cytotoxic agent, of a

therapeutically effective quantity of an isoflavonoid or of an analogue of the chromone type.

8. Method according to Claim 7, in which the isoflavonoid or analogue of the chromone type is administered at the beginning of the chemotherapy treatment and at the beginning of each chemotherapy treatment cycle.